Cellular and molecular basis of von Willebrand disease: Studies on blood outgrowth endothelial cells

Blood

Volumn 121, Issue 14, 2013, Pages 2773-2784

  Starke, Richard D ^a   Paschalaki, Koralia E ^a   Dyer, Clare E F ^b   Harrison Lavoie, Kimberly J ^b   Cutler, Jacqueline A ^c   McKinnon, Thomas A J ^a   Millar, Carolyn M ^a   Cutler, Daniel F ^b   Laffan, Mike A ^a   Randi, Anna M ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c GSTS Pathology   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; POLYMER; VON WILLEBRAND FACTOR;

ADULT; AGED; ARTICLE; CELL GROWTH; CELL LINEAGE; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOTHELIUM CELL; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; MALE; MIDDLE AGED; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN PROCESSING; PROTEIN SECRETION; VON WILLEBRAND DISEASE; CELL CULTURE; CYTOLOGY; GENETICS; METABOLISM; PATHOLOGY; PHYSIOLOGY; WEIBEL PALADE BODY;

ADULT; AGED; CELL LINEAGE; CELLS, CULTURED; ENDOTHELIAL CELLS; FEMALE; HUMANS; MALE; MIDDLE AGED; PHENOTYPE; RNA, MESSENGER; VON WILLEBRAND DISEASE, TYPE 1; VON WILLEBRAND DISEASE, TYPE 2; VON WILLEBRAND FACTOR; WEIBEL-PALADE BODIES;

MLCS; MLOWN;

EID: 84878218994     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-06-435727     Document Type: Article

References (44)

1. Nichols WC, Ginsburg D. von Willebrand disease. Medicine (Baltimore). 1997;76(1):1-20.
2. James PD, Lillicrap D. von Willebrand disease: clinical and laboratory lessons learned from the large von Willebrand disease studies. Am J Hematol. 2012;87(suppl 1):S4-S11.
3. Giblin JP, Hewlett LJ, Hannah MJ. Basal secretion of von Willebrand factor from human endothelial cells. Blood. 2008;112(4):957-964.
4. Metcalf DJ, Nightingale TD, Zenner HL, et al. Formation and function of Weibel-Palade bodies. J Cell Sci. 2008;121(pt 1):19-27.
5. Starke RD, Ferraro F, Paschalaki KE, et al. Endothelial von Willebrand factor regulates angiogenesis. Blood. 2011;117(3):1071-1080.
6. Ingram DA, Mead LE, Tanaka H, et al. Identification of a novel hierarchy of endothelial progenitor cells using human peripheral and umbilical cord blood. Blood. 2004;104(9): 2752-2760.
7. Birdsey GM, Dryden NH, Amsellem V, et al. Transcription factor Erg regulates angiogenesis and endothelial apoptosis through VE-cadherin. Blood. 2008;111(7):3498-3506.
8. O'Donnell J, Boulton FE, Manning RA, et al. Amount of H antigen expressed on circulating von Willebrand factor is modified by ABO blood group genotype and is a major determinant of plasma von Willebrand factor antigen levels. Arterioscler Thromb Vasc Biol. 2002;22(2):335-341.
9. Rosén H, Calafat J, Holmberg L, et al. Sorting of Von Willebrand factor to lysosome-related granules of haematopoietic cells. Biochem Biophys Res Commun. 2004;315(3):671-678.
10. Michaux G, Abbitt KB, Collinson LM, et al. The physiological function of von Willebrand's factor depends on its tubular storage in endothelial Weibel-Palade bodies. Dev Cell. 2006;10(2): 223-232.
11. Baillod P, Affolter B, Kurt GH, et al. Multimeric analysis of von Willebrand factor by vertical sodium dodecyl sulphate agarose gel electrophoresis, vacuum blotting technology and sensitive visualization by alkaline phosphatase anti-alkaline phosphatase complex. Thromb Res. 1992;66(6):745-755.
12. Wang JW, Valentijn KM, de Boer HC, et al. Intracellular storage and regulated secretion of von Willebrand factor in quantitative von Willebrand disease. J Biol Chem. 2011;286(27): 24180-24188.
13. Lyons SE, Bruck ME, Bowie EJ, et al. Impaired intracellular transport produced by a subset of type IIA von Willebrand disease mutations. J Biol Chem. 1992;267(7):4424-4430.
14. Huber D, Cramer EM, Kaufmann JE, et al. Tissuetype plasminogen activator (t-PA) is stored in Weibel-Palade bodies in human endothelial cells both in vitro and in vivo. Blood. 2002;99(10): 3637-3645.
15. Kuo MC, Patschan D, Patschan S, et al. Ischemia-induced exocytosis of Weibel-Palade bodies mobilizes stem cells. J Am Soc Nephrol. 2008;19(12):2321-2330.
16. Huang J, Roth R, Heuser JE, et al. Integrin alpha(v)beta(3) on human endothelial cells binds von Willebrand factor strings under fluid shear stress. Blood. 2009;113(7):1589-1597.
17. Wagner DD. Cell biology of von Willebrand factor. Annu Rev Cell Biol. 1990;6:217-246.
18. Cutler JA, Hadonou M, Madan B, Laffan MA, Mitchell MJ. The identification of a repeat novel frameshift mutation in the VWF gene with an unpredicted effect [abstract]. J Thromb Haemost. 2009;7(suppl s2):PP-WE-635.
19. Sadler JE. von Willebrand factor assembly and secretion. J Thromb Haemost. 2009;7(suppl 1): 24-27.
20. Michaux G, Hewlett LJ, Messenger SL, et al. Analysis of intracellular storage and regulated secretion of 3 von Willebrand disease-causing variants of von Willebrand factor. Blood. 2003; 102(7):2452-2458.
21. Sutherland MS, Cumming AM, Bowman M, et al. A novel deletion mutation is recurrent in von Willebrand disease types 1 and 3. Blood. 2009; 114(5):1091-1098.
22. Federici AB, Canciani MT, Forza I, et al. Ristocetin cofactor and collagen binding activities normalized to antigen levels for a rapid diagnosis of type 2 von Willebrand disease-single center comparison of four different assays. Thromb Haemost. 2000;84(6):1127-1128.
23. Hassenpflug WA, Budde U, Obser T, et al. Impact of mutations in the von Willebrand factor A2 domain on ADAMTS13-dependent proteolysis. Blood. 2006;107(6):2339-2345.
24. Pruss CM, Golder M, Bryant A, et al. Use of a mouse model to elucidate the phenotypic effects of the von Willebrand factor cleavage mutants, Y1605A/M1606A and R1597W. J Thromb Haemost. 2012;10(5):940-950.
25. McKinnon TA, Nowak AA, Cutler J, et al. Characterisation of von Willebrand factor A1 domain mutants I1416N and I1416T: correlation of clinical phenotype with flow-based platelet adhesion. J Thromb Haemost. 2012;10(7): 1409-1416.
26. Bowie EJ, Solberg LA Jr, Fass DN, et al. Transplantation of normal bone marrow into a pig with severe von Willebrand's disease. J Clin Invest. 1986;78(1):26-30.
27. Lin Y, Weisdorf DJ, Solovey A, et al. Origins of circulating endothelial cells and endothelial outgrowth from blood. J Clin Invest. 2000;105(1):71-77.
28. Critser PJ, Yoder MC. Endothelial colony-forming cell role in neoangiogenesis and tissue repair. Curr Opin Organ Transplant. 2010;15(1):68-72.
29. Paschalaki K, Starke RD, Mercado N, et al. Endothelial colony forming cells (ECFC) are senescent and dysfunctional in COPD due to reduced sirtuin-1 levels. Heart. 2011;97(20):e7.
30. Berber E, James PD, Hough C, et al. An assessment of the pathogenic significance of the R924Q von Willebrand factor substitution. J Thromb Haemost. 2009;7(10):1672-1679.
31. Ewenstein BM, Inbal A, Pober JS, et al. Molecular studies of von Willebrand disease: reduced von Willebrand factor biosynthesis, storage, and release in endothelial cells derived from patients with type I von Willebrand disease. Blood. 1990; 75(7):1466-1472.
32. Federici AB, de Groot PG, Moia M, et al. Type I von Willebrand disease, subtype 'platelet low': decreased platelet adhesion can be explained by low synthesis of von Willebrand factor in endothelial cells. Br J Haematol. 1993;83(1): 88-93.
33. Platè M, Duga S, Baronciani L, et al. Premature termination codon mutations in the von Willebrand factor gene are associated with allele-specific and position-dependent mRNA decay. Haematologica. 2010;95(1):172-174.
34. Castaman G, Platè M, Giacomelli SH, et al. Alterations of mRNA processing and stability as a pathogenic mechanism in von Willebrand factor quantitative deficiencies. J Thromb Haemost. 2010;8(12):2736-2742.
35. Ragni MV, Jankowitz RC, Chapman HL, et al. A phase II prospective open-label escalating dose trial of recombinant interleukin-11 in mild von Willebrand disease. Haemophilia. 2008;14(5): 968-977.
36. Mayadas TN, Wagner DD. Vicinal cysteines in the prosequence play a role in von Willebrand factor multimer assembly. Proc Natl Acad Sci USA. 1992;89(8):3531-3535.
37. Goodeve AC. The genetic basis of von Willebrand disease. Blood Rev. 2010;24(3):123-134.
38. O'Brien LA, James PD, Othman M, et al. Association of Hemophilia Clinic Directors of Canada. Founder von Willebrand factor haplotype associated with type 1 von Willebrand disease. Blood. 2003;102(2):549-557.
39. Pruss CM, Golder M, Bryant A, et al. Pathologic mechanisms of type 1 VWD mutations R1205H and Y1584C through in vitro and in vivo mouse models. Blood. 2011;117(16):4358-4366.
40. James PD, Notley C, Hegadorn C, et al. The mutational spectrum of type 1 von Willebrand disease: results from a Canadian cohort study. Blood. 2007;109(1):145-154.
41. Bowen DJ, Collins PW. An amino acid polymorphism in von Willebrand factor correlates with increased susceptibility to proteolysis by ADAMTS13. Blood. 2004;103(3):941-947.
42. Casaña P, Martínez F, Espinós C, et al. Search for mutations in a segment of the exon 28 of the human von Willebrand factor gene: new mutations, R1315C and R1341W, associated with type 2M and 2B variants. Am J Hematol. 1998; 59(1):57-63.
43. Goodeve A, Eikenboom J, Castaman G, et al. Phenotype and genotype of a cohort of families historically diagnosed with type 1 von Willebrand disease in the European study, Molecular and Clinical Markers for the Diagnosis and Management of Type 1 von Willebrand Disease (MCMDM-1VWD). Blood. 2007;109(1):112-121.
44. Ribba AN, Hilbert L, Lavergne JM, et al. The arginine-552-cysteine (R1315C) mutation within the A1 loop of von Willebrand factor induces an abnormal folding with a loss of function resulting in type 2A-like phenotype of von Willebrand disease: study of 10 patients and mutated recombinant von Willebrand factor. Blood. 2001;97(4):952-959.